Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

IGC Pharma (IGC) Return on Sales (2016 - 2025)

IGC Pharma (IGC) has disclosed Return on Sales for 16 consecutive years, with 9.53% as the latest value for Q3 2025.

  • Quarterly Return on Sales fell 537.0% to 9.53% in Q3 2025 from the year-ago period, while the trailing twelve-month figure was 5.83% through Sep 2025, up 480.0% year-over-year, with the annual reading at 5.6% for FY2025, 406.0% up from the prior year.
  • Return on Sales for Q3 2025 was 9.53% at IGC Pharma, down from 4.88% in the prior quarter.
  • The five-year high for Return on Sales was 3.63% in Q1 2025, with the low at 77.57% in Q3 2021.
  • Average Return on Sales over 5 years is 18.47%, with a median of 9.78% recorded in 2024.
  • Peak annual rise in Return on Sales hit 7235bps in 2021, while the deepest fall reached -6432bps in 2021.
  • Over 5 years, Return on Sales stood at 16.77% in 2021, then surged by 60bps to 6.77% in 2022, then plummeted by -304bps to 27.4% in 2023, then surged by 74bps to 7.12% in 2024, then plummeted by -34bps to 9.53% in 2025.
  • According to Business Quant data, Return on Sales over the past three periods came in at 9.53%, 4.88%, and 3.63% for Q3 2025, Q2 2025, and Q1 2025 respectively.